Product Description
Abediterol is a novel, once-daily long-acting ?2-agonist in development for the treatment of chronic obstructive pulmonary disease (COPD) and asthma in combination with an anti-inflammatory agent.
Mechanisms of Action: ADRB2 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Inhalant
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Asthma|Chronic Obstructive Pulmonary Disease
Phase 1: Chronic Obstructive Pulmonary Disease|Asthma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2006-7041-83/hah | N/A |
Not yet recruiting |
Cholangitis, Sclerosing|Oral Ulcer|Colitis, Ulcerative |
2022-12-30 |
|
D6541C00001 | P1 |
Terminated |
Chronic Obstructive Pulmonary Disease |
2020-04-03 |
52% |
D6540C00006 | P1 |
Completed |
Asthma |
2017-11-09 |
|
D7110C00001 | P1 |
Completed |
Chronic Obstructive Pulmonary Disease|Asthma |
2017-04-06 |
52% |